Background-Nitric oxide (NO) and related molecules are thought to inhibit human platelet aggregation by raising levels of cGMP. Methods and Results-Both oxidative stress (reactive oxygen species) and hemoglobin (Hb) seem to oppose NO effects. A major fraction of NO in the blood is bound to thiols of Hb, forming S-nitrosohemoglobin (SNO-Hb), which releases the NO group on deoxygenation in the microcirculation. Here we show that (1) both cell-free and intraerythrocytic SNO-Hb (SNO-RBC) inhibit platelet aggregation, (2) the oxidation state of the hemes in Hb influences the response-SNOmetHb (which is functionally similar to SNO-deoxyHb) has greater platelet inhibitory effects than SNO-oxyHb, and (3) the mechanism of platelet inhibition by SNO-Hb is cGMP independent. Conclusions-We suggest that the RBC has evolved a means to counteract platelet activation in small vessels and the proaggregatory effects of oxidative stress by forming SNO-Hb. (Circulation. 1998;97:263-267.)
I
nhibition of platelet aggregation by EDRF [1] [2] [3] has significant clinical implications, particularly in the arena of vasoocclusive disorders. Extensive experimental evidence shows that the inhibition of platelet function by EDRF/NO, both in vitro and in vivo, is directly associated with activation of soluble guanylate cyclase, which increases the intraplatelet content of the second messenger cGMP. 4, 5 That said, simulations of NO reactions and diffusion and mechanism of activation suggest that this free radical alone cannot account for all of the EDRF bioactivity. 6, 7 Specifically, NO would be scavenged by hemoglobin in RBCs. Accordingly, it has been suggested that more durable and potent SNOs of glutathione or cysteine may contribute to EDRF activity. 8 SNOs have both potent vasorelaxant 9 and platelet inhibitory properties 10, 11 involving activation of soluble guanylate cyclase as well as cGMPindependent actions, including direct modulation of membrane-associated ion channels 12 and enzymes. 13 This broad range of activity reflects the ability of SNOs to regulate both heme-and thiol-containing proteins. 13, 14 We have recently shown that hemoglobin in circulating RBCs transports NO as an S-nitroso adduct of Cys␤93 and releases it selectively at low oxygen tension (PO 2 ) or when the heme is oxidized (metHb). 15 This can be understood by appreciating that Hb exists in two alternative structures named R (high O 2 affinity) and T (low O 2 affinity) and that metHb is structurally similar to T-state Hb; thus, NO is transported bound to Cys␤93 in R structure (high PO 2 ) and released to relax blood vessels in T structure (low PO 2 ). 16 Here we show that (1) SNO-Hb, principally the met form, possesses potent antiaggregatory activity both in cell-free and erythrocytic systems and (2) attenuation of platelet aggregation was not associated with changes in platelet cGMP content as determined by radioimmunoassay. These observations suggest that SNO-Hb can physiologically modulate platelet function without increasing cGMP, ie, in a manner distinct from other SNOs.
Methods

Isolation of PRP and PPP
Venous blood (20 mL) was obtained from healthy volunteers who had not consumed aspirin or other nonsteroidal antiinflammatory drugs for at least 2 weeks and was anticoagulated in 13 mmol/L sodium citrate dihydrate. PRP was prepared by centrifugation of whole blood at 150g for 10 minutes, followed by aspiration of the upper two thirds of the plasma layer. PPP was prepared by centrifuging the remaining blood at 1500g for 15 minutes. An accurate platelet count was obtained with a Coulter Counter (model Z1, Coulter Electronics), and the count was then adjusted to 150 000 platelets per 1 L of PRP with PPP as the diluent.
Syntheses
SNO-cys was prepared by reacting equimolar L-cysteine (in 0.5 eq/L HCl and 0.5 mmol/L EDTA) with NaNO 2 (in distilled water), followed by adjustment of the pH to 7.4 with phosphate buffer. MetHb was prepared by exposing oxyHbA 0 to a 10-fold excess of potassium ferricyanide for 5 minutes; excess ferricyanide was removed by twice desalting the protein over a Sephadex G-25 column. SNO-oxyHb and SNO-metHb were prepared by transnitrosylating oxy or met HbA 0 with a 10-fold excess of SNO-cys for 10 minutes, followed by desalting over a column of Sephadex G-25. The identity and concentration of SNO-oxy/metHb was confirmed by spectro-scopic analysis by use of a Perkins-Elmer (Lambda2S) ultraviolet/ visual dual-beam spectrophotometer. 17 SNO content was quantified by a modified method of Saville 18 as previously described. 16 The S-nitroso hemoglobin derivatives had 2Ϯ0.2 SNO groups per hemoglobin tetramer.
Preparation of Human RBCs Containing
S-Nitrosohemoglobin
After removal of PRP and PPP from whole blood as described above, the remaining RBC pellet was resuspended and washed in PBS (pH 7.4) twice, followed by centrifugation at 1000g. The RBC pellet was resuspended in PBS to a hematocrit of 10%. Hemoglobin was converted to the met (Fe 3ϩ ) form by adding PBS saturated with NO gas to the RBC solution at a ratio of 1:4 (vol/vol). After 5 minutes, RBCs were pelleted at 1000g, followed by four washes in PBS.
To prepare SNO-RBCs, the RBC pellet (either oxyRBC or metRBC) was resuspended to a hematocrit of 10% in 2% borate and 0.9% NaCl, pH 9. A twofold excess of SNO-cys to Hb was then added to the RBC solution, which was incubated for 10 minutes. RBCs were pelleted at 1000g and washed four times with PBS. Lack of residual SNO-cys or free SNO-oxy/metHb (from hemolysis) was confirmed by spectroscopic analysis and assay of the supernatant for SNO. To quantify the intracellular concentration of SNO-Hb, a 500-L aliquot of the final RBC pellet was combined with 1000 L of distilled H 2 O to lyse the RBCs. The lysate was twice desalted over a Sephadex G-25 column, and the concentration of SNO-Hb was determined.
Platelet Aggregation Studies
PRP was incubated with 10
Ϫ8 to 10 Ϫ4 mol/L native oxyHb, native metHb, SNO-oxyHb, or SNO-metHb for 10 minutes at 37°C in a PAP-4 aggregometer (Biodata). Aggregation was then initiated with 10 mol/L ADP. Results were quantified by measurement of the rate or extent of change of light transmittance through the sample cuvette and are expressed as a normalized ratio of percent aggregation in the presence of hemoglobin to that obtained in the absence of the hemoprotein.
For SNO-RBC experiments, PRP (containing 150 000 to 300 000 platelets per 1 L) was incubated at room temperature for 15 minutes with SNO-oxy/met RBCs or native oxy/met RBCs (10 Ϫ6 to 10 Ϫ4 mol/L) followed by differential centrifugation at 50g for 10 minutes to separate the platelets from RBCs. Control incubations of PPP were treated in the same fashion. The resulting PRP was placed in separate cuvettes, baseline transmittance was calibrated with the PPP retrieved from control incubates to normalize platelet counts, and platelet aggregation was initiated by the addition of 10 mol/L ADP.
Platelet cGMP Determination
ADP (10 mol/L) was added to 450 uL of PRP containing 150 000 platelets per 1 L and native oxyHb, SNO-oxyHb, or SNO-metHb. After 1 minute, 300 L of 10% (wt/vol) trichloroacetic acid was added to the platelet mixture to precipitate the proteins. Intraplatelet cGMP was assessed by radioimmunoassay as previously described.
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Materials
Purified human hemoglobin A 0 was kindly supplied by Apex Bioscience. All other chemicals were obtained from Sigma Chemical Co and were of the highest grade.
Statistical Analysis
All values are expressed as the meanϮSEM. Differences in platelet aggregation and platelet cGMP levels in the presence or absence of the various hemoglobins or RBCs were evaluated with a one-way ANOVA, with posttest assessment done with the Bonferroni method. Statistical significance was assumed for PϽ.05. (Fig 1a, open circles) . In contrast, native 
Results
Effect of S-Nitrosylated
Selected Abbreviations and Acronyms
Cys␤93 ϭ cysteine in the ␤ chain of hemoglobin (93 position) EDRF ϭ endothelium-derived relaxing factor NO ϭ nitric oxide PPP ϭ platelet-poor plasma PRP ϭ platelet-rich plasma RBC ϭ red blood cell SNO ϭ S-nitrosothiol SNO-cys ϭ S-nitrosocysteine SNO-metHb ϭ S-nitroso methemoglobin SNO-oxyHb ϭ S-nitroso oxyhemoglobin SNO-RBC ϭ intraerythrocytic S-nitrosylated oxy/met hemoglobin metHb (Fig 1a, closed circles) had little effect on platelet aggregation. SNO-oxyHb (10 Ϫ8 to 10 Ϫ4 mol/L) had appreciably less effect on ADP-evoked platelet aggregation (Fig 1b, closed circles) than SNO-metHb.
Effect of RBCs Containing SNO-RBCs on Platelet Aggregation
Platelets were coincubated with SNO-oxyRBCs, SNOmetRBCs, native oxyRBCs, or native metRBCs for 15 minutes, followed by retrieval of the platelets by differential centrifugation. The coincubation of PRP with 10 Ϫ6 to 10 Ϫ4 mol/L SNOmetRBCs (Fig 2a, hatched bars) produced a dose-dependent attenuation of ADP-induced platelet aggregation that was significantly (PϽ.05) different from native metRBCs (Fig 2a, solid  bars) . SNO-oxyRBCs [final (SNO-oxyHb) of 10 Ϫ6 to 10 Ϫ4 mol/L] had no effect on ADP-induced platelet aggregation (Fig  2b, gray bars) compared with controls. Fig 3 is a representative platelet aggregation tracing illustrating the dose-dependent manner by which SNO-metRBCs inhibited platelet aggregation.
Platelet cGMP Levels After Exposure to Native OxyHb, SNO-oxyHb, or SNO-metHb
Because low-molecular-weight SNOs inhibit platelet aggregation by activation of soluble guanylate cyclase and increases in the second messenger cGMP, the effects of cell-free SNOoxy/metHb on platelet cGMP levels were also assessed. Interestingly, neither SNO-metHb (Fig 4, open bars) nor SNO-oxyHb (Fig 4, hatched bars) had any effect on platelet cGMP content compared with cGMP levels in the presence of native oxyHb (Fig 4, solid bars) .
Discussion
A substantial body of evidence has accumulated highlighting the proaggregatory properties of the RBC. Erythrocytes markedly enhance the platelet release reaction, eicosanoid biosynthesis, and platelet recruitment, 20, 21 effects that can be attenuated in human volunteers by daily ingestion of aspirin. 22 RBCs are also rich sources of ADP, the spontaneous and/or evoked release of which has powerful platelet-activating effects in vitro. 23, 24 Likewise, RBCs contain hemoglobin, which readily scavenges EDRF and NO. Thus, not surprisingly, RBCs have been shown to reverse EDRF-and NO-induced inhibition of intravascular platelet aggregation. How, then, does the platelet contend with the proaggregatory properties of RBCs? The answer may reside, in part, within the platelet. Specifically, both constitutive endothelial and inducible isoforms of NO synthase in the platelet cytosol 27, 28 release NO-related molecules in quantities similar to those liberated by endothelial cells. Thus, the platelet may act in an autocrine or paracrine fashion to inhibit its own activation. The answer may also lie in the vascular endothelium. Indeed, Sprague et al 29 recently found that human RBCs release ATP in response to mechanical deformation; this ATP evokes the release of NO, thereby lowering pulmonary vascular resistance. Endothelial activation in this manner should attenuate platelet aggregation. However, paradoxically, the RBC can mitigate NO-related activity by sequestering it. To counterbalance NO scavenging by the hemes in Hb, RBCs also carry NO attached to HbCys␤93. 16 SNO is released from SNO-Hb in the peripheral vasculature under low oxygen tension and on heme oxidation, thereby modulating arterial blood pressure and blood flow to tissues. 15, 16 In the present study, we expand the biologic properties of SNO-Hb to include inhibition of human platelet aggregation.
The incongruity in SNO-metHb and SNO-oxyHb activities derives partly from their structural differences. Human Hb exists in two conformational states named R (relaxed, high O 2 affinity) and T (tense, low O 2 affinity). 30 Hb transitions from R to T after liberation of the second O 2 molecule, mainly in the flow-regulating resistance blood vessels. 30 The allosteric transition affects NO group release from the thiol [ie, thiol affinity for NO is high in the R-(oxy) structure and low in the T-(deoxy) structure]. The structural and functional behavior of T-state Hb closely resembles that of metHb. That is, SNOmetHb, like T-state SNO-deoxyHb, dilates blood vessels, whereas SNO-oxyHb constricts them. 16 Here we applied these structure-function relations to the platelet by showing the increased potency of SNO-metHb over SNO-oxyHb.
Interestingly, 10% of circulating Hb is normally oxidized to the met form in a 24-hour period, and metHb levels increase during oxidative stresses. NO group release from cys␤93 on heme iron oxidation may serve to inhibit platelet activation engendered by oxidative stress. Thus, this protective function of RBCs may constitute a novel antioxidative mechanism. Equally important, SNO-metHb provides insight into the antiplatelet potential of SNO-oxyHb on assuming the deoxy (T) configuration in peripheral resistance microvessels and capillaries.
SNO-Hb did not affect platelet cGMP content. Although the lack of an increase in platelet cGMP associated with the activity of SNOs is unprecedented, the notion that cGMP does not fully account for the biologic properties of NO/SNO is not new. Indeed, SNO can activate calcium-dependent potassium channels in vascular smooth muscle, 31 reduce cytosolic Ca 2ϩ in guanylate cyclase-deficient fibroblasts, 32 and modulate Ca 2ϩ influx in PC12-64 cells, 33 all in a cGMP-independent manner. Significantly, SNOs can inhibit ATP-dependent Ca 2ϩ uptake into platelet membrane vesicles in the absence of guanylate cyclase or cGMP. 34 The precise cellular mechanism of SNO-Hb-evoked inhibition of platelet aggregation, however, remains to be determined.
In summary, we demonstrate the capacity of SNO-Hb to modulate platelet function independently of cGMP and suggest regulation of this pathway by cellular redox state. These data expand the understanding of NO regulation in general and of SNO-Hb physiology in particular. The potential also exists for exploitation of this system for therapeutic purposes. 
